Lab services provider Barc Lab has entered into a global strategic alliance with OWL Metabolomics to bring metabolomics technology to clinical trials.
The combination of Barc’s central lab services with OWL’s metabolomics technology is expected to aid biopharmaceutical companies engaged in non-alcoholic steatohepatitis (NASH) research.
OWL Metabolomics noted that the alliance will support drug research and help in obtaining better insights into the biological impact of their compounds.
The company’s technology enables the discovery of more than 1,000 small metabolites from a single sample. This is intended for thorough evaluation of the disease complexity by analysing metabolic alterations.
Barc Lab CEO Mario Papillon said: “OWL is known for their strength in the metabolomics field, particularly in liver disease, and offers valuable insight into biological systems.
“This collaboration will allow us to provide our customers with the solutions they need to develop tailored treatments for NASH patients and address this desperate unmet medical need.”
Barc Lab provides central lab services for testing across different fields such as oncology, immunology, genetics, microbiology and clinical pathology.
OWL Metabolomics CEO Pablo Ortiz said: “We are confident that the two companies together will bring a very positive impact to the important field of NASH research and become valued reference service providers for clinical trials in liver disease research.”
This company is focused on offering metabolomics services that will support clinical trials in liver diseases and other human disorders.